Business Wire

Ogletree Deakins and KPMG Law Join Forces in a New Alliance

Share

Ogletree Deakins and KPMG Law in Germany1 are forming a global alliance to provide businesses with global workforce solutions. This alliance will be instrumental in expanding immigration and employment law reach for both organizations and will enable KPMG firms outside of the US2 to bring the US capability and services of Ogletree Deakins to their clients around the world.

The alliance is in response to growing client demand for a technology-powered, globally unified approach to business challenges faced in the areas of immigration and global mobility, labor and employment, and the associated tax, compensation, and benefits issues. This non-exclusive alliance with Ogletree Deakins does not include KPMG in the US or entities that it owns or controls, which do not provide legal services3.

“As businesses expand and look to shore up recovery in the post-pandemic world, there is increasing pressure for multinational organizations seeking to get the right people in the right places at the right time, and in compliance with the requirements of any given jurisdiction,” said Thomas Wolf, Head of Global Immigration Services for the KPMG organization. “Ogletree Deakins’ labor, employment and immigration experience in the United States is a perfect fit for KPMG’s organization of firms as we expand our global legal services practice4 and our global mobility services offerings around the world. We are excited to join forces with Ogletree Deakins to offer clients even deeper global coverage for their pressing employment and immigration legal matters.”

Both Ogletree Deakins and KPMG Law in Germany are leaders in utilizing technology and innovation to enhance client service, including in the areas of artificial intelligence, data analytics and knowledge management. By combining the strengths of both organizations, this new alliance will provide clients with an increased breadth of technology solutions. KPMG Law in Germany is part of the broader KPMG Law / Global Legal Services network across KPMG firms, with 2,800 lawyers in 81 jurisdictions.

“Ogletree Deakins is an international labor and employment firm and has established an extensive network of lawyers practicing in 53 offices across North America and in Europe to meet our clients’ needs. Our alliance with KPMG Law in Germany will benefit clients by complementing our US labor, employment and immigration offerings with ‘end-to-end’ workplace solutions—including tax, compensation, global immigration, and related advisory and consulting services, over a truly global footprint. Our firm shares a vision with the KPMG network for client service, innovation and cutting-edge technology solutions, and we are already working together on a next generation mobility services platform,” said Matt Keen, managing shareholder of Ogletree Deakins.

About Ogletree Deakins

Ogletree Deakins is one of the largest US labor and employment law firms representing management in all types of employment-related legal matters. Premier client service, as outlined in the firm’s Client Pledge, is one of the firm’s top priorities and a cornerstone of its core values. U.S. News – Best Lawyers® “Best Law Firms” has named Ogletree Deakins a “Law Firm of the Year” for 10 consecutive years. In 2021, the publication named Ogletree Deakins its “Law Firm of the Year” in the Litigation – Labor & Employment category. Ogletree Deakins has more than 900 attorneys located in 53 offices across the United States and in Europe, Canada, and Mexico. The firm represents a diverse range of clients, from small businesses to Fortune 50 companies. More: ogletree.com.

About KPMG International

KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: kpmg.com

_______________________________

1 The agreement will be initially signed by KPMG Law Rechtsanwaltsgesellschaft mbH (“KPMG Law in Germany”), which is associated with KPMG AG Wirtschaftsprüfungsgesellschaft, the German member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. Other non-US member firms are expected to join this non-exclusive alliance over the next several months.

2 KPMG Law in Germany was established in 2007 and is an independent corporate law firm associated with KPMG AG Wirtschaftsprüfungsgesellschaft and affiliated with the KPMG International Cooperative. This non-exclusive alliance with Ogletree Deakins does not include the KPMG US member firm or entities that it owns, or controls, which do not provide legal services. For cases where KPMG in the US clients require immigration and/or employment and labor law services, Ogletree Deakins may contract with these clients separately.

3 For cases where KPMG US clients require immigration and/or employment and labor law services, Ogletree Deakins would contract with these clients separately.

4 Certain member firms of the KPMG global organization, including KPMG in the US, do not provide legal services. For the purpose of this press release any commentary will be on general concepts only and is not in any way intended as legal advice or views on laws of any jurisdiction.

Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates and related entities.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ryan King
Ogletree Deakins
(404) 870-1742
ryan.king@ogletree.com

Lauren Ruiz
Ogletree Deakins
(404) 260-0645
lauren.ruiz@ogletree.com

Amy Diaz
KPMG International
(416) 777-3042
amydiaz@kpmg.ca

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

In Celebration of World Rainforest Day, 33 Qualified Teams and 9 Judges Announced in $10M XPRIZE Competition to Improve Understandings and Preservation of the Planet’s Rainforests22.6.2021 18:24:00 CEST | Press release

XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially announced today the teams moving forward in the $10M XPRIZE Rainforest aimed at improving our understanding of the rainforest ecosystem. Sponsored by Alana Foundation, the five-year XPRIZE Rainforest is a call-to-action to help save rainforests through the development of transformative, scalable, and affordable technology to autonomously survey and monitor biodiversity in real-time, leading to insights that communicate the health, well-being, and value of standing tropical rainforests. XPRIZE Rainforest is co-developing an inclusive framework throughout all stages of the competition that ensures competing teams co-design and co-create solutions with Indigenous Peoples and local communities as key stakeholders and not just beneficiaries. These 33 teams will now leverage existing and emerging technologies, such as robotics, remote sensing, data analysis, artificial

BourseInside, The New Media Platform That Finds Attractive Investments for Curious Investors22.6.2021 17:08:00 CEST | Press release

On the stock market, small caps continue to outperform. Since 1926, they have posted a performance of 12.1% per year, in contrast to 9.7% for large caps. And yet these so-called "small stocks" have been largely ignored by the stock market. They are rarely covered by analysts, shunned by the mainstream stock-market press and neglected by funds. Nevertheless, they are of great interest to investors, in particular those who have recently taken to investing in the stock market in order to grow their savings (16% increase in investors in 2020). For half of these newcomers, investing in the stock market gives them the opportunity to support the French economy by supporting the growth of our future champions and to channel their savings into a more sustainable and fairer model. In order to further strengthen this link between the French people and the development of our national companies, we decided to create BourseInside, the first web/TV/newsletter media platform, fully dedicated to listed

DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma22.6.2021 16:31:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the European Commission (EC) has granted marketing authorisation for the expanded use of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation in two new indications. The first authorisation of these new indications is for the use of daratumumab SC in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adults with newly diagnosed systemic light chain (AL) amyloidosis. This approval makes this daratumumab-based regimen the first approved therapy for AL amyloidosis in Europe. The second authorisation is for the use of daratumumab SC in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of adults with multiple myeloma (MM) who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor, and have

PPG Introduces Digital Color-Matching Device for Commercial Vehicles22.6.2021 15:02:00 CEST | Press release

PPG (NYSE: PPG) today announced the introduction of its ColorReader portable digital device, which will enable customers in the commercial vehicle sector to quickly and precisely match colors to the PPG DELFLEET ONE® color palette and international standard colors. ColorReader is a BLUETOOTH®-connected device that works with a dedicated app. Available for iOS and Android tablets and smartphones, the device provides a highly accurate color match in just a few seconds. “All users have to do is download the ColorReader app, connect with their smartphone or tablet, and place ColorReader on the painted surface to scan,” said Jo Thompson, PPG color marketing manager, automotive refinish, Europe, Middle East and Africa. “ColorReader also offers a smart solution when a smartphone or tablet is not available by instantly displaying the three closest matching colors on its built-in display after scanning.” PPG recently launched ColorReader in Europe, the Middle East and Africa, and has received a

Personalis Announces NeXT Level Biomarkers Symposium22.6.2021 15:01:00 CEST | Press release

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced its inaugural event, NeXT Level Biomarkers Symposium, which will showcase novel research into emerging biomarkers using the Personalis NeXT Platform™. This event will detail the latest research from Personalis as well as a case study done in collaboration with the Parker Institute for Cancer Immunotherapy. Presentations from Personalis will focus on recently published research into HLA loss of heterozygosity, neoantigen prediction, as well as Personalis’ novel composite biomarker, the Neoantigen Presentation Score (NEOPS™). In addition, Dr. Theresa LaVallee will be presenting findings from the PRINCE trial based on data developed and analyzed in collaboration with Personalis. The agenda for NeXT Level Biomarkers Symposium will cover: Biomarker Discovery with ImmunoID NeXT Platform® Exploring HLA LOH with the DASH (Deletion of Allele-Specific HLAs) Algorithm Neoantigen Binding Prediction and Bioma

Kymeta Joins the U.S. Army’s Armored Brigade Combat Team Pilot Program22.6.2021 15:00:00 CEST | Press release

Kymeta (www.kymetacorp.com), the communications company making mobile global, announced today that it has been selected to participate in the U.S. Army’s Armored Brigade Combat Team (ABCT) satellite communications on the move (SOTM) pilot program. The program will assess communications solutions on select vehicles to enhance battlefield network and command post communications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005288/en/ The Kymeta u8 is the comprehensive connectivity solution that is available today and enables trusted, secure communications on the go and on the pause with a host of innovative features. (Photo: Business Wire) The ABCT pilot program will be led by General Dynamics Mission Systems, and Kymeta will supply eight u8 terminals for integration and testing on a variety of ABCT vehicles. Kymeta is the world’s first and only metamaterial-based SOTM terminal, and its electronically steered flat pane

Anna Biosciences Launches Pioneering Immunotherapeutic Treatment to Fight COVID-1922.6.2021 15:00:00 CEST | Press release

Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem. The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease. Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem P